Ionis Pharmaceuticals, Inc. (IONS) Analyst Ratings & Price Targets

Ionis Pharmaceuticals, Inc.

IONS · NASDAQ-GS

Analyst Consensus

Buy

20 analysts

$43

Current

—

Low

$85

Average

—

High

Average target implies +98.26% versus the current price.

Analyst Ratings Synthesis

The supplied consensus rating and number of analysts backing each rating are unknown. TipRanks does report 18 analysts offering 12-month targets, with an average of $90.13, a low of $68, and a high of $115; the range is $47 wide, but the evidence does not identify a target cluster or attribute the most and least bullish forecasts to specific firms. The only explicit action during the week was HC Wainwright’s reduction to $100 from $115, a bearish revision. Fintel also reported an average target of $89, without a comparable prior figure. The substantive reason for the target spread is not disclosed, so the evidence establishes disagreement in valuation, not its underlying assumptions.

Rating Actions

No individual rating actions have been captured for IONS yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CITIGROUP

GUGGENHEIM SEC.

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: IONS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NASDAQ-GS

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Key Issues

Bullish view

TipRanks reports 18 analysts with an average 12-month target of $90.13 and a high target of $115, indicating that published expectations remain materially above the $58.09 prior close.

Bearish view

HC Wainwright reduced its target from $115 to $100 and the shares opened at $52.15 after the downgrade, showing that at least one analyst became less constructive and that sentiment is sensitive to valuation or outlook changes.

Analyst Consensus

See all

Buy

20 analysts

$43

Current

—

Low

$85

Average

—

High

Average target implies +98.26% versus the current price.

Earnings History

BeatMissNo estimate

Ionis Pharmaceuticals, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers